Topic: National Cancer Research Network
Conditions
Interventions
Study interventions will begin prior to the start of chemo/immunosuppression and continue until recovery of the neutrophil count to greater than 1.0 x 10^9/L. If fungal infection occurs, then testing
Sponsors
Barts and The London NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Informed consent 2. Patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL) undergoing intensive chemotherapy (predicted neutropenia of less than 0.5 x 10^9/L for greater than 10 days) and/or receiving high dose steroids 3. Patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) 4. Patients requiring high dose steroids for graft versus host disease post HSCT 5. Patients with a history of probable or proven invasive aspergillosis and having chemotherapy, regardless of their underlying haematological malignancy 6. Aged greater than 18 years, either sex
Exclusion criteria
Exclusion criteria: 1. Inability to give informed consent 2. Patients aged less than 18 years 3. Pre-existing chest disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GM ELISA from serum and BALF, measured within 6 months of the conclusion of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured within 6 months of the conclusion of the study: 1. To establish cut off points to rule IA in or out 2. GM Elisa in prognosis 3. Inflamatory marker and cytokine profil in EBC 4. Non-invasive EBC in IA 5. PCR for Aspergillus 6. PCR for Aspergillus from blood and BALF 7. Repeated measures over time or a combination of markers 8. Role of BAL | — |
Countries
United Kingdom
Outcome results
None listed